BG102214A - Derivatives of azetidinons for the treatment of atherosclerosis - Google Patents

Derivatives of azetidinons for the treatment of atherosclerosis

Info

Publication number
BG102214A
BG102214A BG102214A BG10221498A BG102214A BG 102214 A BG102214 A BG 102214A BG 102214 A BG102214 A BG 102214A BG 10221498 A BG10221498 A BG 10221498A BG 102214 A BG102214 A BG 102214A
Authority
BG
Bulgaria
Prior art keywords
alkyl
optionally
aryl
value
whichcan
Prior art date
Application number
BG102214A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dashyant Dhanak
Deirdre HICKEY
Robert IFE
Colin LEACH
David TEW
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG102214A publication Critical patent/BG102214A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG102214A 1995-07-01 1998-01-28 Derivatives of azetidinons for the treatment of atherosclerosis BG102214A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
PCT/EP1996/002765 WO1997002242A1 (en) 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
BG102214A true BG102214A (en) 1998-08-31

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102214A BG102214A (en) 1995-07-01 1998-01-28 Derivatives of azetidinons for the treatment of atherosclerosis

Country Status (23)

Country Link
EP (1) EP0840725A1 (hu)
JP (1) JP2002515852A (hu)
KR (1) KR19990028630A (hu)
CN (1) CN1197452A (hu)
AP (1) AP728A (hu)
AU (1) AU708032B2 (hu)
BG (1) BG102214A (hu)
BR (1) BR9609445A (hu)
CA (1) CA2225627A1 (hu)
CZ (1) CZ422197A3 (hu)
EA (1) EA199800109A1 (hu)
HU (1) HUP9901153A3 (hu)
IL (1) IL122650A0 (hu)
MA (1) MA23922A1 (hu)
MX (1) MX9800186A (hu)
NO (1) NO976158L (hu)
NZ (1) NZ311684A (hu)
OA (1) OA10648A (hu)
PE (1) PE8998A1 (hu)
PL (1) PL324240A1 (hu)
SK (1) SK178497A3 (hu)
TR (1) TR199701762T1 (hu)
WO (1) WO1997002242A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
TR199802160T2 (xx) * 1996-04-26 1999-04-21 Smithkline Beecham Plc Ateroskleroz tedavisi i�in azetidinon t�revleri.
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
SK287296B6 (sk) 2000-02-16 2010-06-07 Smithkline Beecham Plc Pyrimidín-4-ónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
KR101563753B1 (ko) 2007-05-11 2015-10-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 피부 궤양의 치료 방법
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP5277243B2 (ja) 2007-05-11 2013-08-28 トーマス・ジェファーソン・ユニバーシティ 神経変性疾患および障害を治療および阻止する方法
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
EP2725024A4 (en) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
KR20140059204A (ko) 2011-07-27 2014-05-15 글락소 그룹 리미티드 비시클릭 피리미돈 화합물
EP2739627A4 (en) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
EP2948457A4 (en) 2013-01-25 2016-09-07 Glaxosmithkline Ip Dev Ltd COMPOUNDS
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
MX2022005615A (es) 2019-11-09 2022-07-27 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo.
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
MX9704736A (es) * 1994-12-22 1997-10-31 Smithkline Beecham Plc Acetidin 2-onas sustituidas, procedimiento para prepararlas, uso de las mismas y composiciones que las contienen.

Also Published As

Publication number Publication date
EP0840725A1 (en) 1998-05-13
NZ311684A (en) 2000-04-28
HUP9901153A3 (en) 1999-11-29
PE8998A1 (es) 1998-03-20
OA10648A (en) 2002-09-25
AU708032B2 (en) 1999-07-29
CZ422197A3 (cs) 1998-06-17
SK178497A3 (en) 1998-07-08
CA2225627A1 (en) 1997-01-23
JP2002515852A (ja) 2002-05-28
BR9609445A (pt) 1999-04-06
NO976158D0 (no) 1997-12-30
IL122650A0 (en) 1998-08-16
CN1197452A (zh) 1998-10-28
AU6305096A (en) 1997-02-05
TR199701762T1 (xx) 1998-05-21
PL324240A1 (en) 1998-05-11
KR19990028630A (ko) 1999-04-15
MA23922A1 (fr) 1996-12-31
NO976158L (no) 1998-02-25
MX9800186A (es) 1998-07-31
AP728A (en) 1999-01-29
HUP9901153A2 (hu) 1999-08-30
AP9701161A0 (en) 1998-01-31
EA199800109A1 (ru) 1998-10-29
WO1997002242A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
BG102214A (en) Derivatives of azetidinons for the treatment of atherosclerosis
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
MX9705590A (es) Compuestos heterociclicos sustituidos, procedimiento para su preparacion y composiciones que los contienen.
ATE27810T1 (de) 2-(3-iod-2-propinyloxy)-ethanol-carbamate, ihre herstellung und ihre verwendung als antimikrobielle substanzen.
AU2647495A (en) Novel potent inducers of terminal differentiation and methods of use thereof
ES2134815T3 (es) Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos.
TR199701173T1 (xx) Yeni arilglisinamid t�revleri, bunlar�n �retilmesine mahsus usul.
TR199802160T2 (xx) Ateroskleroz tedavisi i�in azetidinon t�revleri.
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
MX9706394A (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
HU9402444D0 (en) Diacyl-substituted guanidine derivatives, process for producing them and pharmaceutical compositions containing them
PL315052A1 (en) Condensed dihydropyridines, method of obtaining them, their application in producing pharmaceutic preparations and pharmaceutic preparations containing such compounds
TW238304B (en) A process for the preparation of 1-substituted-5(4H)-tetrazolinones
GR3023757T3 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents.
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
GB9612600D0 (en) Chemical compounds
RU98112496A (ru) Производные 5-нафталин-1-ил-1,3-диоксана, их получение и терапевтическое применение
DE69810294T2 (de) Calixaren-röhren als kationenrezeptoren
GB9908021D0 (en) Pharmaceutical compounds
MX9804482A (es) Quinolinas y quinazolinas utiles en terapias.
ES2056025A1 (es) Nuevos derivados de indol.
EP0165032A3 (en) Dihydropyridine anti-ischaemic and antihypertensive agents